# Attovia Therapeutics

> Attovia Therapeutics is a San Carlos, California clinical-stage biotech developing first-in-class multispecific biologics for immune-mediated diseases. Its proprietary ATTOBODY platform builds small-format, biparatopic nanobody medicines with ultra-high (picomolar) affinity, tunable half-life and fast tissue penetration - engineered to hit multiple disease pathways at once. Lead programs ATTO-1310 (anti-IL-31) and ATTO-3712 (IL-13 x IL-31 bispecific) target chronic pruritus and atopic dermatitis. Founded in 2023 out of an Alamar Biosciences and Frazier Life Sciences incubation, the company has raised roughly $255M across Series A through C.

- **Founded:** 2023
- **Headquarters:** San Carlos, California, United States
- **Founders:** Tao Fu (Co-Founder & CEO), Petter Veiby (Co-Founder & Chief Scientific Officer), Hangjun Zhan (Co-Founder & Chief Technology Officer), Zaneta Odrowaz (Co-Founder & Chief Business Officer), Yuling Luo (Co-Founder & Director)
- **Team size:** ~53 employees
- **Products:** ATTOBODY Platform, ATTO-1310, ATTO-3712
- **Notable:** Raised approximately $255M across Series A, B and C within roughly two years of founding., Advanced two first-in-class programs (ATTO-1310, ATTO-3712) toward and into Phase 1., Built the proprietary ATTOBODY multispecific nanobody platform with reported 4-5 month target-to-lead timelines.

## Products & services

- **ATTOBODY Platform** — A proprietary, modular protein-design platform that generates small-format, biparatopic nanobody binders with low picomolar affinity, enhanced specificity, tunable half-life, fast tissue penetration and the ability to engage multiple targets/pathways in a single therapeutic. Supports multispecifics, half-life extension and payload conjugation.
- **ATTO-1310** — First-in-class, half-life-extended anti-IL-31 biologic in Phase 1 for chronic pruritus of unknown origin (CPUO) and other pruritic conditions, designed for fast-acting efficacy.
- **ATTO-3712** — First-in-class IL-13 x IL-31 bispecific, half-life-extended, targeting atopic dermatitis, chronic spontaneous urticaria, prurigo nodularis and other inflammatory skin conditions; Phase 1 planned for H2 2025.

## Achievements

- Raised approximately $255M across Series A, B and C within roughly two years of founding.
- Advanced two first-in-class programs (ATTO-1310, ATTO-3712) toward and into Phase 1.
- Built the proprietary ATTOBODY multispecific nanobody platform with reported 4-5 month target-to-lead timelines.
- Attracted a syndicate of leading life-science investors including Deep Track Capital, Sanofi Ventures and Vida Ventures.

## Latest updates

- **2025-04** — Closed $90M Series C led by Deep Track Capital to advance ATTO-1310 and ATTO-3712 through clinical proof-of-concept.
- **2025-07** — Planned initiation of Phase 1 study for ATTO-3712 (IL-13 x IL-31 bispecific) in H2 2025.
- **2024-12** — CEO Tao Fu profiled by Illumina Ventures on Attovia's platform strategy and speed of discovery.

## Links

- Website: https://attovia.com
- LinkedIn: https://www.linkedin.com/company/attovia-therapeutics

---

Profile page: https://yespress.io/attovia-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-13